Sofwave Medical Ltd. announced market approval for Sofwave's(TM) SUPERB Technology in Mexico. Approval was granted by Mexico'sFood and Drug Administration, the Federal Commission for the Protection from Sanitary Risks (COFEPRIS), a division of the Mexico's Ministry of Health. The company has regulatory submissions pending in other large markets including the People's Republic of China and Japan.

Additionally, the company has also recently received U.S. Food and Drug Administration clearance to expand SUPERB's treatment indications to be used for the short-term improvement in the appearance of cellulite.